UBS Downgrades Catalent to Neutral, Raises Price Target to $63.5
Portfolio Pulse from Benzinga Newsdesk
UBS analyst John Sourbeer downgraded Catalent (NYSE:CTLT) from Buy to Neutral but raised the price target from $58 to $63.5.

February 06, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Catalent was downgraded by UBS from Buy to Neutral, although the price target was increased from $58 to $63.5.
The downgrade to Neutral suggests a more cautious outlook on Catalent's stock by UBS, potentially due to perceived limited upside or increased risks. However, the increase in the price target indicates a positive adjustment to the expected stock value, suggesting that while the stock might not outperform, it is still expected to grow in value. This mixed signal could lead to short-term uncertainty among investors, likely resulting in neutral impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100